Critical Care Management of Gastrointestinal Bleeding and Ascites in Liver Failure

Abstract

Gastrointestinal (GI) bleeding and ascites are two significant clinical events that frequently present in critically ill patients with chronic liver failure or decompensated cirrhosis. GI bleeding in patients with cirrhosis, particularly portal hypertensive-associated bleeding, carries a high short-term mortality (15–25%) and requires early initiation of a vasoactive agent and antibiotics as well as timely endoscopic management. Conservative transfusion strategies and adequate airway protection are also imperative to assist in bleeding control. The presence of ascites among hospitalized cirrhotics requires early analysis of ascitic fluid to diagnose spontaneous bacterial peritonitis and initiate appropriate antibiotics and albumin to reduce patients' high associated mortality rates of greater than 25%. Appropriate utilization of portal decompression using transjugular intrahepatic portosystemic shunt placement for selected patients with failure to control bleeding or ascites and early consideration for liver transplantation referral is critical to improve patient survival. This review will aim to elucidate the current strategies for the management of critically ill patients with chronic liver failure presenting with GI bleeding or ascites.

Keywords

chronic liver failure - gastrointestinal bleeding - varices - portal hypertension - ascites

• References

• 1 Odelowo OO, Smoot DT, Kim K. Upper gastrointestinal bleeding in patients with liver cirrhosis. J Natl Med Assoc 2002; 94 (08) 712-715
• 2 Niu B, Kim B, Limketkai BN. , et al. Mortality from spontaneous bacterial peritonitis among hospitalized patients in the USA. Dig Dis Sci 2018; 63 (05) 1327-1333
• 3 Fortune B, Cardenas A. Ascites, refractory ascites and hyponatremia in cirrhosis. Gastroenterol Rep (Oxf) 2017; 5 (02) 104-112
• 4 Savage SA, Sumislawski JJ, Zarzaur BL, Dutton WP, Croce MA, Fabian TC. The new metric to define large-volume hemorrhage: results of a prospective study of the critical administration threshold. J Trauma Acute Care Surg 2015; 78 (02) 224-229 , discussion 229–230
• 5 Duchesne JC, Heaney J, Guidry C. , et al. Diluting the benefits of hemostatic resuscitation: a multi-institutional analysis. J Trauma Acute Care Surg 2013; 75 (01) 76-82
• 6 Ley EJ, Clond MA, Srour MK. , et al. Emergency department crystalloid resuscitation of 1.5 L or more is associated with increased mortality in elderly and nonelderly trauma patients. J Trauma 2011; 70 (02) 398-400
• 7 Neal MD, Hoffman MK, Cuschieri J. , et al. Crystalloid to packed red blood cell transfusion ratio in the massively transfused patient: when a little goes a long way. J Trauma Acute Care Surg 2012; 72 (04) 892-898
• 8 Villanueva C, Colomo A, Bosch A. , et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368 (01) 11-21
• 9 Odutayo A, Desborough MJ, Trivella M. , et al. Restrictive versus liberal blood transfusion for gastrointestinal bleeding: a systematic review and meta-analysis of randomised controlled trials. Lancet Gastroenterol Hepatol 2017; 2 (05) 354-360
• 10 Kravetz D, Bosch J, Arderiu M, Pilar Pizcueta M, Rodés J. Hemodynamic effects of blood volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: influence of the extent of portal-systemic shunting. Hepatology 1989; 9 (06) 808-814
• 11 Cerqueira RM, Andrade L, Correia MR, Fernandes CD, Manso MC. Risk factors for in-hospital mortality in cirrhotic patients with oesophageal variceal bleeding. Eur J Gastroenterol Hepatol 2012; 24 (05) 551-557
• 12 McCormick PA, Jenkins SA, McIntyre N, Burroughs AK. Why portal hypertensive varices bleed and bleed: a hypothesis. Gut 1995; 36 (01) 100-103
• 13 Dzik WH, Kirkley SA. Citrate toxicity during massive blood transfusion. Transfus Med Rev 1988; 2 (02) 76-94
• 14 Howland WS, Schweizer O, Carlon GC, Goldiner PL. The cardiovascular effects of low levels of ionized calcium during massive transfusion. Surg Gynecol Obstet 1977; 145 (04) 581-586
• 15 Smith HM, Farrow SJ, Ackerman JD, Stubbs JR, Sprung J. Cardiac arrests associated with hyperkalemia during red blood cell transfusion: a case series. Anesth Analg 2008; 106 (04) 1062-1069
• 16 Sahu S, , Hemlata, Verma A. Adverse events related to blood transfusion. Indian J Anaesth 2014; 58 (05) 543-551
• 17 Kermode JC, Zheng Q, Milner EP. Marked temperature dependence of the platelet calcium signal induced by human von Willebrand factor. Blood 1999; 94 (01) 199-207
• 18 Jurkovich GJ, Greiser WB, Luterman A, Curreri PW. Hypothermia in trauma victims: an ominous predictor of survival. J Trauma 1987; 27 (09) 1019-1024
• 19 Sperry JL, Ochoa JB, Gunn SR. , et al; Inflammation the Host Response to Injury Investigators. An FFP:PRBC transfusion ratio >/=1:1.5 is associated with a lower risk of mortality after massive transfusion. J Trauma 2008; 65 (05) 986-993
• 20 Practice guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 1996; 84 (03) 732-747
• 21 Maltz GS, Siegel JE, Carson JL. Hematologic management of gastrointestinal bleeding. Gastroenterol Clin North Am 2000; 29 (01) 169-187 , vii
• 22 Shaz BH, Dente CJ, Nicholas J. , et al. Increased number of coagulation products in relationship to red blood cell products transfused improves mortality in trauma patients. Transfusion 2010; 50 (02) 493-500
• 23 Borgman MA, Spinella PC, Perkins JG. , et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma 2007; 63 (04) 805-813
• 24 Perkins JG, Cap AP, Spinella PC. , et al. An evaluation of the impact of apheresis platelets used in the setting of massively transfused trauma patients. J Trauma 2009; 66 (4, Suppl): S77-S84 , discussion S84–S85
• 25 Inaba K, Lustenberger T, Rhee P. , et al. The impact of platelet transfusion in massively transfused trauma patients. J Am Coll Surg 2010; 211 (05) 573-579
• 26 Holcomb JB, Tilley BC, Baraniuk S. , et al; PROPPR Study Group. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 2015; 313 (05) 471-482
• 27 Scalea TM, Bochicchio KM, Lumpkins K. , et al. Early aggressive use of fresh frozen plasma does not improve outcome in critically injured trauma patients. Ann Surg 2008; 248 (04) 578-584
• 28 Snyder CW, Weinberg JA, McGwin Jr G. , et al. The relationship of blood product ratio to mortality: survival benefit or survival bias?. J Trauma 2009; 66 (02) 358-362 , discussion 362–364
• 29 Franchini M, Lippi G. Fibrinogen replacement therapy: a critical review of the literature. Blood Transfus 2012; 10 (01) 23-27
• 30 Rossaint R, Bouillon B, Cerny V. , et al; Task Force for Advanced Bleeding Care in Trauma. Management of bleeding following major trauma: an updated European guideline. Crit Care 2010; 14 (02) R52
• 31 Bosch J, Thabut D, Albillos A. , et al; International Study Group on rFVIIa in UGI Hemorrhage. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial. Hepatology 2008; 47 (05) 1604-1614
• 32 Bendtsen F, D'Amico G, Rusch E. , et al. Effect of recombinant factor VIIa on outcome of acute variceal bleeding: an individual patient based meta-analysis of two controlled trials. J Hepatol 2014; 61 (02) 252-259
• 33 Martí-Carvajal AJ, Karakitsiou DE, Salanti G. Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases. Cochrane Database Syst Rev 2012; (03) CD004887
• 34 Bosch J, Thabut D, Bendtsen F. , et al; European Study Group on rFVIIa in UGI Haemorrhage. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004; 127 (04) 1123-1130
• 35 Marks PW. Hematologic manifestations of liver disease. Semin Hematol 2013; 50 (03) 216-221
• 36 Weeder PD, Porte RJ, Lisman T. Hemostasis in liver disease: implications of new concepts for perioperative management. Transfus Med Rev 2014; 28 (03) 107-113
• 37 Mallett SV, Chowdary P, Burroughs AK. Clinical utility of viscoelastic tests of coagulation in patients with liver disease. Liver Int 2013; 33 (07) 961-974
• 38 De Pietri L, Ragusa F, Deleuterio A, Begliomini B, Serra V. Reduced transfusion during OLT by POC coagulation management and TEG functional fibrinogen: a retrospective observational study. Transplant Direct 2015; 2 (01) e49
• 39 Pihusch R, Rank A, Göhring P, Pihusch M, Hiller E, Beuers U. Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease. J Hepatol 2002; 37 (05) 548-555
• 40 Ben-Ari Z, Panagou M, Patch D. , et al. Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography. J Hepatol 1997; 26 (03) 554-559
• 41 Razzaghi A, Barkun AN. Platelet transfusion threshold in patients with upper gastrointestinal bleeding: a systematic review. J Clin Gastroenterol 2012; 46 (06) 482-486
• 42 Rudolph SJ, Landsverk BK, Freeman ML. Endotracheal intubation for airway protection during endoscopy for severe upper GI hemorrhage. Gastrointest Endosc 2003; 57 (01) 58-61
• 43 Koch DG, Arguedas MR, Fallon MB. Risk of aspiration pneumonia in suspected variceal hemorrhage: the value of prophylactic endotracheal intubation prior to endoscopy. Dig Dis Sci 2007; 52 (09) 2225-2228
• 44 Koenig SJ, Lakticova V, Mayo PH. Utility of ultrasonography for detection of gastric fluid during urgent endotracheal intubation. Intensive Care Med 2011; 37 (04) 627-631
• 45 Wilcox SR, Bittner EA, Elmer J. , et al. Neuromuscular blocking agent administration for emergent tracheal intubation is associated with decreased prevalence of procedure-related complications. Crit Care Med 2012; 40 (06) 1808-1813
• 46 Mosier JM, Sakles JC, Stolz U. , et al. Neuromuscular blockade improves first-attempt success for intubation in the intensive care unit. A propensity matched analysis. Ann Am Thorac Soc 2015; 12 (05) 734-741
• 47 Toy P, Popovsky MA, Abraham E. , et al; National Heart, Lung and Blood Institute Working Group on TRALI. Transfusion-related acute lung injury: definition and review. Crit Care Med 2005; 33 (04) 721-726
• 48 Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA. ; TRALI Consensus Panel. Proceedings of a consensus conference: towards an understanding of TRALI. Transfus Med Rev 2005; 19 (01) 2-31
• 49 Fatalities Reported to FDA Following Blood Collection and Transfusion: Annual Summary for Fiscal Year 2016. Silver Spring, MD: U.S. Food and Drug Administration; 2016
• 50 Gajic O, Rana R, Winters JL. , et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. Am J Respir Crit Care Med 2007; 176 (09) 886-891
• 51 Khan H, Belsher J, Yilmaz M. , et al. Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients. Chest 2007; 131 (05) 1308-1314
• 52 Toy P, Gajic O, Bacchetti P. , et al; TRALI Study Group. Transfusion-related acute lung injury: incidence and risk factors. Blood 2012; 119 (07) 1757-1767
• 53 Fung YL, Silliman CC. The role of neutrophils in the pathogenesis of transfusion-related acute lung injury. Transfus Med Rev 2009; 23 (04) 266-283
• 54 Bux J, Sachs UJ. The pathogenesis of transfusion-related acute lung injury (TRALI). Br J Haematol 2007; 136 (06) 788-799
• 55 Silliman CC. The two-event model of transfusion-related acute lung injury. Crit Care Med 2006; 34 (5, Suppl): S124-S131
• 56 Sihler KC, Napolitano LM. Complications of massive transfusion. Chest 2010; 137 (01) 209-220
• 57 Tobian AA, Sokoll LJ, Tisch DJ, Ness PM, Shan H. N-terminal pro-brain natriuretic peptide is a useful diagnostic marker for transfusion-associated circulatory overload. Transfusion 2008; 48 (06) 1143-1150
• 58 Skeate RC, Eastlund T. Distinguishing between transfusion related acute lung injury and transfusion associated circulatory overload. Curr Opin Hematol 2007; 14 (06) 682-687
• 59 Narick C, Triulzi DJ, Yazer MH. Transfusion-associated circulatory overload after plasma transfusion. Transfusion 2012; 52 (01) 160-165
• 60 Habib A, Sanyal AJ. Acute variceal hemorrhage. Gastrointest Endosc Clin N Am 2007; 17 (02) 223-252 , v
• 61 Prandi D, Rueff B, Roche-Sicot J. , et al. Life-threatening hemorrhage of the digestive tract in cirrhotic patients. An assessment of the postoperative mortality after emergency portacaval shunt. Am J Surg 1976; 131 (02) 204-209
• 62 de Franchis R. ; Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63 (03) 743-752
• 63 Ioannou G, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev 2003; (01) CD002147
• 64 Wells M, Chande N, Adams P. , et al. Meta-analysis: vasoactive medications for the management of acute variceal bleeds. Aliment Pharmacol Ther 2012; 35 (11) 1267-1278
• 65 Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 2017; 65 (01) 310-335
• 66 Bloom SR, Polak JM. Somatostatin. Br Med J (Clin Res Ed) 1987; 295 (6593): 288-290
• 67 Bañares R, Albillos A, Rincón D. , et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology 2002; 35 (03) 609-615
• 68 Gotzsche PC. Somatostatin or octreotide for acute bleeding oesophageal varices. Cochrane Database Syst Rev 2000; (02) CD000193
• 69 Villanueva C, Ortiz J, Sàbat M. , et al. Somatostatin alone or combined with emergency sclerotherapy in the treatment of acute esophageal variceal bleeding: a prospective randomized trial. Hepatology 1999; 30 (02) 384-389
• 70 Huang CC, Sheen IS, Chu CM. , et al. A prospective randomized controlled trial of sandostatin and vasopressin in the management of acute bleeding esophageal varices. Changge-ng Yi-xue Zazhi 1992; 15 (02) 78-83
• 71 Song KB, Kim SC, Kim JH. , et al. Prognostic value of somatostatin receptor subtypes in pancreatic neuroendocrine tumors. Pancreas 2016; 45 (02) 187-192
• 72 Saari A, Klvilaakso E, Inberg M. , et al. Comparison of somatostatin and vasopressin in bleeding esophageal varices. Am J Gastroenterol 1990; 85 (07) 804-807
• 73 Jenkins SA, Baxter JN, Corbett W, Devitt P, Ware J, Shields R. A prospective randomised controlled clinical trial comparing somatostatin and vasopressin in controlling acute variceal haemorrhage. Br Med J (Clin Res Ed) 1985; 290 (6464): 275-278
• 74 Planas R, Quer JC, Boix J. , et al. A prospective randomized trial comparing somatostatin and sclerotherapy in the treatment of acute variceal bleeding. Hepatology 1994; 20 (02) 370-375
• 75 D'Amico G, Politi F, Morabito A. , et al. Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial. Hepatology 1998; 28 (05) 1206-1214
• 76 Primignani M, Andreoni B, Carpinelli L. , et al. Sclerotherapy plus octreotide versus sclerotherapy alone in the prevention of early rebleeding from esophageal varices: a randomized, double-blind, placebo-controlled, multicenter trial. New Italian Endoscopic Club. Hepatology 1995; 21 (05) 1322-1327
• 77 Sung JJ, Chung SC, Yung MY. , et al. Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation. Lancet 1995; 346 (8991-8992): 1666-1669
• 78 Besson I, Ingrand P, Person B. , et al. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med 1995; 333 (09) 555-560
• 79 Avgerinos A, Nevens F, Raptis S, Fevery J. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet 1997; 350 (9090): 1495-1499
• 80 D'amico G, Criscuoli V, Fili D, Mocciaro F, Pagliaro L. Meta-analysis of trials for variceal bleeding. Hepatology 2002; 36 (4, Pt 1): 1023-1024 , author reply 1024–1025
• 81 Seo YS, Park SY, Kim MY. , et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology 2014; 60 (03) 954-963
• 82 Imperiale TF, Teran JC, McCullough AJ. A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage. Gastroenterology 1995; 109 (04) 1289-1294
• 83 Baik SK, Jeong PH, Ji SW. , et al. Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am J Gastroenterol 2005; 100 (03) 631-635
• 84 Blei AT, Groszmann RJ, Gusberg R, Conn HO. Comparison of vasopressin and triglycyl-lysine vasopressin on splanchnic and systemic hemodynamics in dogs. Dig Dis Sci 1980; 25 (09) 688-694
• 85 Bosch J, Groszmann RJ, García-Pagán JC. , et al. Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: a placebo-controlled clinical trial. Hepatology 1989; 10 (06) 962-968
• 86 Groszmann RJ, Kravetz D, Bosch J. , et al. Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension. Hepatology 1982; 2 (06) 757-762
• 87 Gimson AE, Westaby D, Hegarty J, Watson A, Williams R. A randomized trial of vasopressin and vasopressin plus nitroglycerin in the control of acute variceal hemorrhage. Hepatology 1986; 6 (03) 410-413
• 88 Tsai YT, Lay CS, Lai KH. , et al. Controlled trial of vasopressin plus nitroglycerin vs. vasopressin alone in the treatment of bleeding esophageal varices. Hepatology 1986; 6 (03) 406-409
• 89 Soares-Weiser K, Brezis M, Tur-Kaspa R, Leibovici L. Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding. Cochrane Database Syst Rev 2002; (02) CD002907
• 90 Fernández J, Navasa M, Gómez J. , et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35 (01) 140-148
• 91 Bernard B, Grangé JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999; 29 (06) 1655-1661
• 92 Pauwels A, Mostefa-Kara N, Debenes B, Degoutte E, Lévy VG. Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection. Hepatology 1996; 24 (04) 802-806
• 93 Soriano G, Guarner C, Tomás A. , et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 1992; 103 (04) 1267-1272
• 94 Soares-Weiser K, Brezis M, Tur-Kaspa R, Paul M, Yahav J, Leibovici L. Antibiotic prophylaxis of bacterial infections in cirrhotic inpatients: a meta-analysis of randomized controlled trials. Scand J Gastroenterol 2003; 38 (02) 193-200
• 95 Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F. , et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review. Aliment Pharmacol Ther 2011; 34 (05) 509-518
• 96 Hou MC, Lin HC, Liu TT. , et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology 2004; 39 (03) 746-753
• 97 Fernández J, Ruiz del Arbol L, Gómez C. , et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006; 131 (04) 1049-1056 , quiz 1285
• 98 Garcia-Tsao G, Sanyal AJ, Grace ND, Carey WD. ; Practice Guidelines Committee of American Association for Study of Liver Diseases; Practice Parameters Committee of American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol 2007; 102 (09) 2086-2102
• 99 Kaviani MJ, Hashemi MR, Kazemifar AR. , et al. Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial. Aliment Pharmacol Ther 2003; 17 (02) 211-216
• 100 Chan WH, Khin LW, Chung YF, Goh YC, Ong HS, Wong WK. Randomized controlled trial of standard versus high-dose intravenous omeprazole after endoscopic therapy in high-risk patients with acute peptic ulcer bleeding. Br J Surg 2011; 98 (05) 640-644
• 101 Shaheen NJ, Stuart E, Schmitz SM. , et al. Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial. Hepatology 2005; 41 (03) 588-594
• 102 Lo EA, Wilby KJ, Ensom MH. Use of proton pump inhibitors in the management of gastroesophageal varices: a systematic review. Ann Pharmacother 2015; 49 (02) 207-219
• 103 Kang SH, Yim HJ, Kim SY. , et al. Proton pump inhibitor therapy is associated with reduction of early bleeding risk after prophylactic endoscopic variceal band ligation: a retrospective cohort study. Medicine (Baltimore) 2016; 95 (08) e2903
• 104 O'Leary JG, Reddy KR, Wong F. , et al; North American Consortium for the Study of End-Stage Liver Disease. Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol 2015; 13 (04) 753-9.e1 , 2
• 105 Altraif I, Handoo FA, Aljumah A. , et al. Effect of erythromycin before endoscopy in patients presenting with variceal bleeding: a prospective, randomized, double-blind, placebo-controlled trial. Gastrointest Endosc 2011; 73 (02) 245-250
• 106 Escorsell À, Pavel O, Cárdenas A. , et al; Variceal Bleeding Study Group. Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial. Hepatology 2016; 63 (06) 1957-1967
• 107 de Franchis R, Primignani M. Why do varices bleed?. Gastroenterol Clin North Am 1992; 21 (01) 85-101
• 108 Monescillo A, Martínez-Lagares F, Ruiz-del-Arbol L. , et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004; 40 (04) 793-801
• 109 Garcia-Pagán JC, Di Pascoli M, Caca K. , et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol 2013; 58 (01) 45-50
• 110 Holster IL, Tjwa ET, Moelker A. , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + β-blocker for prevention of variceal rebleeding. Hepatology 2016; 63 (02) 581-589
• 111 Pomier-Layrargues G, Villeneuve JP, Deschênes M. , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut 2001; 48 (03) 390-396
• 112 Jalan R, Forrest EH, Stanley AJ. , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology 1997; 26 (05) 1115-1122
• 113 Sanyal AJ, Freedman AM, Luketic VA. , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Ann Intern Med 1997; 126 (11) 849-857
• 114 Rössle M, Deibert P, Haag K. , et al. Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet 1997; 349 (9058): 1043-1049
• 115 García-Pagán JC, Caca K, Bureau C. , et al; Early TIPS (Transjugular Intrahepatic Portosystemic Shunt) Cooperative Study Group. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010; 362 (25) 2370-2379
• 116 Conejo I, Guardascione MA, Tandon P. , et al. Multicenter external validation of risk stratification criteria for patients with variceal bleeding. Clin Gastroenterol Hepatol 2018; 16 (01) 132-139.e8
• 117 Garcia-Tsao G. Management of acute variceal hemorrhage as a model of individualized care for patients with cirrhosis. Clin Gastroenterol Hepatol 2018; 16 (01) 24-26
• 118 Suhocki PV, Lungren MP, Kapoor B, Kim CY. Transjugular intrahepatic portosystemic shunt complications: prevention and management. Semin Intervent Radiol 2015; 32 (02) 123-132
• 119 Ripamonti R, Ferral H, Alonzo M, Patel NH. Transjugular intrahepatic portosystemic shunt-related complications and practical solutions. Semin Intervent Radiol 2006; 23 (02) 165-176
• 120 Kerlan Jr RK, LaBerge JM, Baker EL. , et al. Successful reversal of hepatic encephalopathy with intentional occlusion of transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 1995; 6 (06) 917-921
• 121 Monnin-Bares V, Thony F, Sengel C, Bricault I, Leroy V, Ferretti G. Stent-graft narrowed with a lasso catheter: an adjustable TIPS reduction technique. J Vasc Interv Radiol 2010; 21 (02) 275-280
• 122 Fanelli F, Salvatori FM, Rabuffi P. , et al. Management of refractory hepatic encephalopathy after insertion of TIPS: long-term results of shunt reduction with hourglass-shaped balloon-expandable stent-graft. AJR Am J Roentgenol 2009; 193 (06) 1696-1702
• 123 Madoff DC, Wallace MJ. Reduced stents and stent-grafts for the management of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation. Semin Intervent Radiol 2005; 22 (04) 316-328
• 124 Srinivasa RN, Srinivasa RN, Chick JFB, Hage A, Saad WA. Transjugular intrahepatic portosystemic shunt reduction using the GORE VIATORR controlled expansion endoprosthesis: hemodynamics of reducing an established 10-mm TIPS to 8-mm in diameter. Cardiovasc Intervent Radiol 2018; 41 (03) 518-521
• 125 Schepis F, Vizzutti F, Garcia-Tsao G. , et al. Under-dilated TIPS associate with efficacy and reduced encephalopathy in a prospective, non-randomized study of patients with cirrhosis. Clin Gastroenterol Hepatol 2018; 16 (07) 1153-1162.e7
• 126 Sarin SK, Jain AK, Jain M, Gupta R. A randomized controlled trial of cyanoacrylate versus alcohol injection in patients with isolated fundic varices. Am J Gastroenterol 2002; 97 (04) 1010-1015
• 127 Romero-Castro R, Ellrichmann M, Ortiz-Moyano C. , et al. EUS-guided coil versus cyanoacrylate therapy for the treatment of gastric varices: a multicenter study (with videos). Gastrointest Endosc 2013; 78 (05) 711-721
• 128 Mishra SR, Sharma BC, Kumar A, Sarin SK. Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: a randomized controlled trial. J Hepatol 2011; 54 (06) 1161-1167
• 129 Mishra SR, Chander Sharma B, Kumar A, Sarin SK. Endoscopic cyanoacrylate injection versus beta-blocker for secondary prophylaxis of gastric variceal bleed: a randomised controlled trial. Gut 2010; 59 (06) 729-735
• 130 Hung HH, Chang CJ, Hou MC. , et al. Efficacy of non-selective β-blockers as adjunct to endoscopic prophylactic treatment for gastric variceal bleeding: a randomized controlled trial. J Hepatol 2012; 56 (05) 1025-1032
• 131 Cheng LF, Wang ZQ, Li CZ, Lin W, Yeo AE, Jin B. Low incidence of complications from endoscopic gastric variceal obturation with butyl cyanoacrylate. Clin Gastroenterol Hepatol 2010; 8 (09) 760-766
• 132 Lo GH, Liang HL, Chen WC. , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy 2007; 39 (08) 679-685
• 133 Chau TN, Patch D, Chan YW, Nagral A, Dick R, Burroughs AK. “Salvage” transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding. Gastroenterology 1998; 114 (05) 981-987
• 134 Choi YH, Yoon CJ, Park JH, Chung JW, Kwon JW, Choi GM. Balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding: its feasibility compared with transjugular intrahepatic portosystemic shunt. Korean J Radiol 2003; 4 (02) 109-116
• 135 Barange K, Péron JM, Imani K. , et al. Transjugular intrahepatic portosystemic shunt in the treatment of refractory bleeding from ruptured gastric varices. Hepatology 1999; 30 (05) 1139-1143
• 136 Kitamoto M, Imamura M, Kamada K. , et al. Balloon-occluded retrograde transvenous obliteration of gastric fundal varices with hemorrhage. AJR Am J Roentgenol 2002; 178 (05) 1167-1174
• 137 Anderson CL, Saad WE, Kalagher SD. , et al. Effect of transjugular intrahepatic portosystemic shunt placement on renal function: a 7-year, single-center experience. J Vasc Interv Radiol 2010; 21 (09) 1370-1376
• 138 Ninoi T, Nishida N, Kaminou T. , et al. Balloon-occluded retrograde transvenous obliteration of gastric varices with gastrorenal shunt: long-term follow-up in 78 patients. AJR Am J Roentgenol 2005; 184 (04) 1340-1346
• 139 Shimoda R, Horiuchi K, Hagiwara S. , et al. Short-term complications of retrograde transvenous obliteration of gastric varices in patients with portal hypertension: effects of obliteration of major portosystemic shunts. Abdom Imaging 2005; 30 (03) 306-313
• 140 Akahoshi T, Hashizume M, Tomikawa M. , et al. Long-term results of balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding and risky gastric varices: a 10-year experience. J Gastroenterol Hepatol 2008; 23 (11) 1702-1709
• 141 Cho SK, Shin SW, Lee IH. , et al. Balloon-occluded retrograde transvenous obliteration of gastric varices: outcomes and complications in 49 patients. AJR Am J Roentgenol 2007; 189 (06) W365-72
• 142 Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992; 117 (03) 215-220
• 143 Ginés P, Quintero E, Arroyo V. , et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7 (01) 122-128
• 144 Runyon BA. ; AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49 (06) 2087-2107
• 145 Runyon BA. Refractory ascites. Semin Liver Dis 1993; 13 (04) 343-351
• 146 Arroyo V, Ginès P, Gerbes AL. , et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23 (01) 164-176
• 147 Singh V, Dhungana SP, Singh B. , et al. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. J Hepatol 2012; 56 (02) 348-354
• 148 Luca A, Feu F, García-Pagán JC. , et al. Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites. Hepatology 1994; 20 (1, Pt 1): 30-33
• 149 Kravetz D, Romero G, Argonz J. , et al. Total volume paracentesis decreases variceal pressure, size, and variceal wall tension in cirrhotic patients. Hepatology 1997; 25 (01) 59-62
• 150 Bernardi M, Caraceni P, Navickis RJ. Does the evidence support a survival benefit of albumin infusion in patients with cirrhosis undergoing large-volume paracentesis?. Expert Rev Gastroenterol Hepatol 2017; 11 (03) 191-192
• 151 Peltekian KM, Wong F, Liu PP, Logan AG, Sherman M, Blendis LM. Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites. Am J Gastroenterol 1997; 92 (03) 394-399
• 152 Runyon BA. ; AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology 2013; 57 (04) 1651-1653
• 153 Ginès A, Fernández-Esparrach G, Monescillo A. , et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111 (04) 1002-1010
• 154 Ochs A, Rössle M, Haag K. , et al. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 1995; 332 (18) 1192-1197
• 155 Somberg KA, Lake JR, Tomlanovich SJ, LaBerge JM, Feldstein V, Bass NM. Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function. Hepatology 1995; 21 (03) 709-716
• 156 Salerno F, Cammà C, Enea M, Rössle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007; 133 (03) 825-834
• 157 Kim JJ, Tsukamoto MM, Mathur AK. , et al. Delayed paracentesis is associated with increased in-hospital mortality in patients with spontaneous bacterial peritonitis. Am J Gastroenterol 2014; 109 (09) 1436-1442
• 158 Crossley IR, Williams R. Spontaneous bacterial peritonitis. Gut 1985; 26 (04) 325-331
• 159 França A, Giordano HM, Sevá-Pereira T, Soares EC. Five days of ceftriaxone to treat spontaneous bacterial peritonitis in cirrhotic patients. J Gastroenterol 2002; 37 (02) 119-122
• 160 Dalmau D, Layrargues GP, Fenyves D, Willems B, Turgeon F, Turgeon P. Cefotaxime, desacetyl-cefotaxime, and bactericidal activity in spontaneous bacterial peritonitis. J Infect Dis 1999; 180 (05) 1597-1602
• 161 Felisart J, Rimola A, Arroyo V. , et al. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology 1985; 5 (03) 457-462
• 162 Navasa M, Follo A, Llovet JM. , et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 1996; 111 (04) 1011-1017
• 163 Runyon BA, McHutchison JG, Antillon MR, Akriviadis EA, Montano AA. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. Gastroenterology 1991; 100 (06) 1737-1742
• 164 Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol 2013; 11 (02) 123-30.e1
• 165 Sigal SH, Stanca CM, Fernandez J, Arroyo V, Navasa M. Restricted use of albumin for spontaneous bacterial peritonitis. Gut 2007; 56 (04) 597-599
• 166 Sort P, Navasa M, Arroyo V. , et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341 (06) 403-409
• 167 Haq I, Tripathi D. Recent advances in the management of variceal bleeding. Gastroenterol Rep (Oxf) 2017; 5 (02) 113-126
• 168 Bureau C, Thabut D, Oberti F. , et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology 2017; 152 (01) 157-163
• 169 Caraceni P, Riggio O, Angeli P. , et al; ANSWER Study Investigators. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet 2018; 391 (10138): 2417-2429
• 170 Mellinger JL, Volk ML. Multidisciplinary management of patients with cirrhosis: a need for care coordination. Clin Gastroenterol Hepatol 2013; 11 (03) 217-223